Can Bupropion (Wellbutrin) Be Prescribed for ADHD in Patients with Hypertension?
Bupropion can be prescribed for ADHD in patients with hypertension, but requires mandatory baseline blood pressure assessment and close monitoring throughout treatment, as the medication can elevate blood pressure and may exacerbate pre-existing hypertension. 1
Key Considerations from FDA Labeling
The FDA label explicitly warns that treatment with Wellbutrin XL can result in elevated blood pressure and hypertension 1. The labeling mandates:
- Assess blood pressure before initiating treatment
- Monitor blood pressure periodically during treatment
In clinical trials for seasonal affective disorder, bupropion caused:
- Mean systolic BP increase of 1.3 mmHg (statistically significant, p=0.013)
- 2% of patients (11/537) developed hypertension versus 0% on placebo
- 2 patients discontinued due to hypertension 1
Critically, in a trial of patients with stable congestive heart failure, bupropion was associated with exacerbation of pre-existing hypertension in 2 subjects, leading to treatment discontinuation 1.
Evidence on Blood Pressure Effects
In Hypertensive Patients
A dedicated study in adults with untreated mild hypertension (stage 1: SBP 140-159 mmHg) found that bupropion SR 300 mg/day resulted in less SBP reduction compared to placebo (-4.20 vs -6.53 mmHg; p=0.020), though 24-hour ambulatory BP measurements showed no significant differences 2. This suggests bupropion may blunt natural BP improvements but doesn't necessarily cause dramatic elevations in all patients.
In ADHD Populations
In adults with ADHD, bupropion caused a statistically significant increase of +5.9 mmHg in systolic BP (p<0.05) 3. New-onset hypertension (BP ≥140/90) occurred in 10% of patients on active ADHD medications (including bupropion) versus 8% on placebo 3.
Recent pharmacovigilance data shows bupropion has the highest reported odds ratio for hypertension (ROR=3.5,95% CI: 3.3-3.7) among norepinephrine-dopamine reuptake inhibitors 4.
Efficacy for ADHD
Bupropion XL demonstrates clear efficacy for adult ADHD:
- 53% responder rate versus 31% placebo (p=0.004) 5
- Effect size of 0.6 for ADHD Rating Scale 5
- 76% response rate (≥30% symptom reduction) versus 37% placebo 6
Clinical Algorithm for Prescribing
Step 1: Pre-Treatment Assessment
- Measure baseline BP (must be documented)
- If BP is uncontrolled (≥140/90 mmHg), optimize antihypertensive therapy first before initiating bupropion
- If BP is controlled (<140/90 mmHg on medications), proceed with caution
Step 2: Initiation Strategy
- Start at lower dose (150 mg/day) rather than standard dosing
- Titrate slowly to minimize BP effects
- Maximum dose 450 mg/day (do not exceed to reduce seizure risk) 1
Step 3: Monitoring Protocol
- Check BP at 2 weeks after initiation (when response begins) 5
- Check BP at 4 weeks
- Check BP at 8 weeks
- Then monitor every 3 months during maintenance
Step 4: Management of BP Elevation
- If BP increases to ≥140/90 mmHg or increases >10 mmHg from baseline: intensify antihypertensive therapy
- If BP remains uncontrolled despite medication adjustment: discontinue bupropion and consider alternative ADHD treatments (atomoxetine, guanfacine, or clonidine—which may actually lower BP) 7
Alternative Considerations
For patients with difficult-to-control hypertension, consider FDA-approved nonstimulants that lower BP:
- Guanfacine extended-release or clonidine extended-release may be preferable as they can decrease BP and heart rate 7
- These agents have FDA approval for ADHD and provide dual benefit in hypertensive patients
Common Pitfalls to Avoid
- Do not prescribe bupropion without baseline BP documentation—this is an FDA-mandated safety requirement 1
- Do not assume "mild" hypertension is safe—the exacerbation risk exists even in stable patients 1
- Do not combine with MAOIs or other dopaminergic/noradrenergic agents—this significantly increases hypertension risk 1
- Do not abruptly discontinue if switching to guanfacine/clonidine—these require tapering to avoid rebound hypertension 7